PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SPDR S&P Biotech ETF (XBI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

ETF Info

ISINUS78464A8707
CUSIP78464A870
IssuerState Street
Inception DateFeb 6, 2006
RegionNorth America (U.S.)
CategoryHealth & Biotech Equities
Index TrackedS&P Biotechnology Select Industry Index
Home Pagewww.ssga.com
Asset ClassEquity

Asset Class Size

Multi-Cap

Asset Class Style

Growth

Expense Ratio

The SPDR S&P Biotech ETF has a high expense ratio of 0.35%, indicating higher-than-average management fees.


Expense ratio chart for XBI: current value at 0.35% compared with the broader market ranging from 0.00% to 2.12%.0.50%1.00%1.50%2.00%0.35%

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


SPDR S&P Biotech ETF

Popular comparisons: XBI vs. IBB, XBI vs. LABU, XBI vs. ARKG, XBI vs. FBT, XBI vs. KWEB, XBI vs. IBBQ, XBI vs. VOO, XBI vs. ARKK, XBI vs. BIB, XBI vs. SWPPX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in SPDR S&P Biotech ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%NovemberDecember2024FebruaryMarchApril
29.32%
21.11%
XBI (SPDR S&P Biotech ETF)
Benchmark (^GSPC)

S&P 500

Returns By Period

SPDR S&P Biotech ETF had a return of -5.15% year-to-date (YTD) and 4.29% in the last 12 months. Over the past 10 years, SPDR S&P Biotech ETF had an annualized return of 7.70%, while the S&P 500 had an annualized return of 10.55%, indicating that SPDR S&P Biotech ETF did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-5.15%6.30%
1 month-9.48%-3.13%
6 months26.25%19.37%
1 year4.29%22.56%
5 years (annualized)-0.31%11.65%
10 years (annualized)7.70%10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-2.08%12.57%-3.59%
2023-7.80%-9.30%14.03%18.25%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of XBI is 19, indicating that it is in the bottom 19% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of XBI is 1919
SPDR S&P Biotech ETF(XBI)
The Sharpe Ratio Rank of XBI is 1818Sharpe Ratio Rank
The Sortino Ratio Rank of XBI is 2020Sortino Ratio Rank
The Omega Ratio Rank of XBI is 2020Omega Ratio Rank
The Calmar Ratio Rank of XBI is 1818Calmar Ratio Rank
The Martin Ratio Rank of XBI is 1818Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


XBI
Sharpe ratio
The chart of Sharpe ratio for XBI, currently valued at 0.11, compared to the broader market-1.000.001.002.003.004.000.11
Sortino ratio
The chart of Sortino ratio for XBI, currently valued at 0.36, compared to the broader market-2.000.002.004.006.008.000.36
Omega ratio
The chart of Omega ratio for XBI, currently valued at 1.04, compared to the broader market1.001.502.001.04
Calmar ratio
The chart of Calmar ratio for XBI, currently valued at 0.05, compared to the broader market0.002.004.006.008.0010.000.05
Martin ratio
The chart of Martin ratio for XBI, currently valued at 0.24, compared to the broader market0.0010.0020.0030.0040.0050.0060.000.24
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.92, compared to the broader market-1.000.001.002.003.004.001.92
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.78, compared to the broader market-2.000.002.004.006.008.002.78
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market1.001.502.001.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.47, compared to the broader market0.002.004.006.008.0010.001.47
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.64, compared to the broader market0.0010.0020.0030.0040.0050.0060.007.64

Sharpe Ratio

The current SPDR S&P Biotech ETF Sharpe ratio is 0.11. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
0.11
1.92
XBI (SPDR S&P Biotech ETF)
Benchmark (^GSPC)

Dividends

Dividend History

SPDR S&P Biotech ETF granted a 0.02% dividend yield in the last twelve months. The annual payout for that period amounted to $0.02 per share.


PeriodTTM20232022202120202019201820172016201520142013
Dividend$0.02$0.02$0.00$0.04$0.28$0.00$0.20$0.20$0.15$0.43$0.67$0.07

Dividend yield

0.02%0.02%0.00%0.04%0.20%0.00%0.28%0.24%0.26%0.61%1.07%0.17%

Monthly Dividends

The table displays the monthly dividend distributions for SPDR S&P Biotech ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDec
2024$0.00$0.00$0.00
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.01
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2021$0.00$0.00$0.04$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2020$0.00$0.00$0.00$0.00$0.00$0.02$0.00$0.00$0.09$0.00$0.00$0.18
2019$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2018$0.00$0.00$0.06$0.00$0.00$0.06$0.00$0.00$0.07$0.00$0.00$0.01
2017$0.00$0.00$0.02$0.00$0.00$0.11$0.00$0.00$0.04$0.00$0.00$0.03
2016$0.00$0.00$0.06$0.00$0.00$0.05$0.00$0.00$0.03$0.00$0.00$0.02
2015$0.00$0.00$0.08$0.00$0.00$0.15$0.00$0.00$0.05$0.00$0.00$0.15
2014$0.00$0.00$0.11$0.00$0.00$0.21$0.00$0.00$0.19$0.00$0.00$0.16
2013$0.01$0.00$0.00$0.02$0.00$0.00$0.03$0.00$0.00$0.01

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2024FebruaryMarchApril
-51.30%
-3.50%
XBI (SPDR S&P Biotech ETF)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the SPDR S&P Biotech ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the SPDR S&P Biotech ETF was 63.89%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current SPDR S&P Biotech ETF drawdown is 51.30%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-63.89%Feb 9, 2021317May 11, 2022
-49.25%Jul 20, 2015144Feb 11, 2016484Jan 12, 2018628
-37.59%Aug 15, 2008139Mar 5, 2009533Apr 14, 2011672
-35.26%Jun 21, 2018129Dec 24, 2018346May 11, 2020475
-29.07%Feb 28, 201449May 8, 2014120Oct 28, 2014169

Volatility

Volatility Chart

The current SPDR S&P Biotech ETF volatility is 7.21%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%NovemberDecember2024FebruaryMarchApril
7.21%
3.58%
XBI (SPDR S&P Biotech ETF)
Benchmark (^GSPC)